

---

HTA - - Health Technology Assessment Report

## **Dornase alfa for patients with cystic fibrosis: a review of the clinical efficacy and cost-effectiveness (Structured abstract)**

**Code:** HTA-32014000134 **Year:** 2013 **Date:** 2013

**Author:** CADTH

### **Study design (if review, criteria of inclusion for studies)**

A limited literature search was conducted of key resources, and titles and abstracts of the retrieved publications were reviewed. Full-text publications were evaluated for final article selection according to predetermined criteria (population, intervention, comparator, outcomes, and study designs).

### **Participants**

CF patients with moderate to severe chronic pulmonary disease

### **Interventions**

Dornase alfa (Pulmozyme) - a purified solution for inhalation of recombinant human deoxyribonuclease (rhDNase)

### **Outcome measures**

clinical effectiveness, cost effectiveness

### **Main results**

The literature search produced 136 citations, with no additional studies identified from the grey literature. Of these, 21 were deemed potentially relevant and 3 met the criteria for inclusion in this review: 1 systematic review, 1 randomized controlled trial, and one economic evaluation.

<http://onlinelibrary.wiley.com/doi/10.1111/hta.12134/frame.html>

### **See also**

Health Technology Assessment Database

### **Keywords**

Adolescent; Child; Deoxyribonuclease; Airway clearance drugs -expectorants- mucolytic- mucociliary-; hydration; Hypertonic Solutions; Infant; pharmacological\_intervention; Respiratory System Agents; Dornase alpha; Pulmozyme; Inhalation OR nebulised; nebuliser;